Acne vulgaris
Drug research and approvals for acne vulgaris: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 52 studies of acne vulgaris are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 52
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 1
- Gut Microbiome Diversity in Adults With Inflammatory and Immune-Mediated Skin DiseasesNCT07944196 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Apr 11, 2026
- Safety, Tolerability, and Clinical Effectiveness of Adapalene/Clindamycin Phosphate Gel (Klenzit®-C) in Vietnamese…NCT07918001 · Phase 4 · IR INNOVATE RESEARCH PRIVATE LIMITED · starts Feb 25, 2026
- Comparing Nadifloxacin Plus Tretinoin Versus Clindamycin Plus Tretinoin Creams for Mild-to-Moderate AcneNCT07915648 · Phase 4 · Nishtar Medical University · starts Sep 17, 2026
- Evaluating a Brightening Serum for Post-Inflammatory HyperpigmentationNCT07896486 · Not applicable · Weill Medical College of Cornell University · starts Nov 4, 2026
- Comparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne…NCT07883538 · Not applicable · Pak Emirates Military Hospital · starts Oct 8, 2026
- Observational Assessment of Skin Appearance Changes During PRX S Cosmetic Treatment in Participants With Acne-Prone SkinNCT07866131 · Not applicable · WiQo S.p.A. · starts Sep 21, 2026
- Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne (AURORA)NCT07863193 · Phase 3 · Sagimet Biosciences Inc. · starts Oct 21, 2026
- Dermal and Ophthalmological Acceptability and Comedogenicity Assessment of a Cosmetic ProductNCT07848555 · Not applicable · Brainfarma Industria Química e Farmacêutica S/A · starts Sep 8, 2026
- Facial Skin Microbiome in Patients With Moderate-to-Severe Acne Vulgaris Treated With IsotretinoinNCT07834138 · Not reported · Can Tho University of Medicine and Pharmacy · starts Jan 13, 2026
Approved 24 of 34
- Benzoyl peroxideReleases active oxygen
- AdapaleneRetinoic acid receptor agonist
- TretinoinRetinoic acid receptor agonist
- TazaroteneRetinoic acid receptor agonist
- DapsoneDihydropteroate synthase 1 inhibitor
- Clindamycin phosphateBacterial 70S ribosome inhibitor
- IsotretinoinRetinoic acid receptor agonist
- DoxycyclineMatrix metalloproteinase 7 inhibitor
- MinocyclineBacterial 70S ribosome inhibitor
- ClascoteroneAndrogen Receptor antagonist
- TrifaroteneRetinoic acid receptor gamma agonist
- Salicylic acid
- Ethinyl estradiolEstrogen receptor alpha agonist
- DrospirenoneMineralocorticoid receptor antagonist
- Sarecycline
- Azelaic acid
- NorgestimateProgesterone receptor agonist
- Retinol
- Niacinamide
- OfloxacinBacterial DNA gyrase inhibitor
- Norethindrone acetateProgesterone receptor agonist
- Bithionol
- ChloramphenicolBacterial 70S ribosome inhibitor
- DexamethasoneGlucocorticoid receptor agonist
Phase 3 11
- Berdazimer sodiumReleases NO, antimicrobial
- AzithromycinBacterial 70S ribosome inhibitor
- Olumacostat glasaretilAcetyl-CoA carboxylase inhibitor
- KetoconazoleCytochrome P450 51 inhibitor
- MontelukastCysteinyl leukotriene receptor 1 antagonist
- SpironolactoneMineralocorticoid receptor antagonist
- OxytetracyclineBacterial 70S ribosome inhibitor
- Omega-3-ACID ethyl esters
- NadifloxacinBacterial DNA gyrase inhibitor
- Trichloroacetic acid
- Lymecycline
Phase 2 12 of 30
- Methyl aminolevulinateDNA inhibitor
- OmigananCell membrane disrupting agent
- Aminolevulinic acidDNA inhibitor
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- DimethylcurcuminAndrogen Receptor degrader
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- LevamisoleNicotinic acetylcholine receptor alpha subunit agonist
- FinasterideSteroid 5-alpha-reductase 2 inhibitor
- ZileutonArachidonate 5-lipoxygenase inhibitor
- CalcipotrieneVitamin D receptor agonist
- IvermectinGlutamate-gated chloride channel modulator
- ApremilastPhosphodiesterase 4 inhibitor
Phase 1 or earlier 5
- Ascorbic acidSupplement
- Lemuteporfin
- MinoxidilSulfonylurea receptor 2, Kir6.2 opener
- Tofa
- TetracyclineBacterial 70S ribosome inhibitor
How its trials ended
656 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 130 whose ending is known, 71% met their primary endpoint, 2% missed it and 28% stopped early.
- Completed, result not reported38559%
- Met its primary endpoint9214%
- Status unknown7712%
- Ongoing6410%
- Stopped: other or unclear223%
- Stopped: enrollment or feasibility61%
- Stopped: sponsor or business decision51%
- Stopped: funding3<1%
- Missed its primary endpoint2<1%
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Oct 17, 2025 | WinleviClascoterone | Cassiopea S.p.A. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA